|
|
Founded in 1973, Abingworth is a leading international life sciences investment group and part of global investment firm Carlyle (NASDAQ: CG). The company invests across all stages of company development including early and late-stage venture financing, growth equity, and public companies. With offices in London, Boston and Menlo Park, Abingworth has backed 185 developing life science/medical businesses, over two-thirds of which have gone public, merged, or been acquired. Abingworth has funds under management of more than $1.25 billion. The firm has raised eleven funds since it was founded in 1973, the last nine of which have been entirely dedicated to life sciences and healthcare. Abingworth's investments are based in the U.S. and Europe including the U.K., Belgium, Denmark, France, Germany, Holland and Sweden. The firm's investments range from $15-30 million over more than one round of financing. In February 2014, the firm announced the final closing of its POUND 225M ($375M) fund, Abingworth Bioventures VI (ABV VI). ABV VI is Abingworth's 10th life sciences fund. Abingworth has raised 13 funds dedicated to investing in life sciences and healthcare. The firm's most recent, Abingworth Bioventures 8 and Abingworth Clinical Co-Development Fund 2, raised $465 million and $582 million respectively and are actively investing. Within the life sciences market the firm participates in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software.
|
